Related Experiment Videos
Ecto-ATP diphosphohydrolase/CD39 is overexpressed in differentiated human melanomas
K N Dzhandzhugazyan1, A F Kirkin, P thor Straten
1Department of Tumor Cell Biology, Institute of Cancer Biology, Danish Cancer Society, Copenhagen, Denmark.
FEBS Letters
|August 4, 1998
Summary
Melanoma cells show increased ecto-ATPase activity, primarily via CD39, which may help them evade immune detection. This enzyme
Area of Science:
- Biochemistry
- Cancer Biology
- Immunology
Background:
- Ecto-ATPases play roles in cellular processes.
- Melanoma progression involves complex molecular changes.
- Immune evasion is a key mechanism in cancer survival.
Purpose of the Study:
- To compare ecto-ATPase activity in melanocytes and melanoma cell lines.
- To identify the specific ecto-ATPase involved in melanoma.
- To explore the role of CD39 in melanoma progression and immune evasion.
Main Methods:
- Enzymatic assays to measure ecto-ATPase activity.
- Analysis of CD39 expression and mRNA levels in melanoma cells.
- Comparison of enzyme activity across different stages of melanoma.
Main Results:
- Ecto-ATPase activity significantly increased in differentiated melanomas compared to normal melanocytes.
- CD39/ecto-ATP diphosphohydrolase (ATPDase) was identified as the major ecto-ATP-hydrolyzing enzyme.
- CD39 expression and mRNA levels mirrored the observed activity pattern, decreasing with tumor progression.
Conclusions:
- CD39 is upregulated in early-stage melanomas and its activity correlates with disease progression.
- Overexpression of CD39 may facilitate melanoma immune evasion by reducing T-lymphocyte interactions.
- Targeting CD39 could be a potential strategy for melanoma treatment.